Temporalis muscle thickness as a biomarker for sarcopenia: correlation with appendicular skeletal muscle mass in healthy older adults

Andrew Huynh, Scott Wrigley, John J. Andrews, Belinda M. Brown, Sanka Amadoru, Qiongshi Lu, Ting Ye, Jeremiah J. Peiffer, Paul K. Crane, C. Rowe, Louise M. Burrell, Paul A YatesAlzheimer 2025 · DOI

TL;DR

This study explores the temporalis muscle thickness (TMT) as a potential, non-invasive biomarker for sarcopenia, a condition linked to cognitive decline and Alzheimer's disease (AD). Researchers found a moderate correlation between TMT and appendicular skeletal muscle mass (ASM) in healthy older adults, suggesting TMT could be a practical MRI-based diagnostic tool for sarcopenia in AD research.

What Problem Does This Paper Address?

Sarcopenia, the age-related loss of muscle mass, strength, and function, is increasingly recognized as a factor associated with dementia and Alzheimer's disease (AD). Current diagnostic methods for sarcopenia often rely on appendicular skeletal muscle mass (ASM) measured by dual-energy X-ray absorptiometry (DXA). However, DXA is not routinely performed in AD studies. Brain magnetic resonance imaging (MRI) is, however, commonly used in AD research. This presents a challenge: how can sarcopenia be assessed efficiently within the context of AD studies when DXA is not readily available? This paper investigates whether temporalis muscle thickness (TMT), measurable via MRI, could serve as a practical alternative biomarker for sarcopenia in this population.

Methods

The researchers conducted a retrospective study using data from the "Intense Physical Activity and Cognition" study. They analyzed MRI and DXA scans from healthy, cognitively unimpaired older adults that were acquired during the same visit. Temporalis muscle thickness (TMT) was measured on axial T1-weighted MRIs. The measurements were taken bilaterally, perpendicular to the long axis of the temporalis muscle, using the orbital roof and Sylvian fissure as anatomical landmarks. The average TMT was used for analysis. Appendicular skeletal muscle mass (ASM) was adjusted for body size (height²). Sarcopenia was defined according to the 2019 European working group on sarcopenia in older people criteria: ASM < 7.0 kg/m² for males and < 5.5 kg/m² for females. Pearson correlation was used to assess the relationship between TMT and ASM, as well as between TMT and age.

Datasets

The study utilized data from the "Intense Physical Activity and Cognition" study, which included healthy, cognitively unimpaired older adults. No new datasets were introduced.

Key Insights and Ideas

  • Bridging the Gap: The core idea is to leverage the common use of MRI in AD research to assess sarcopenia, bypassing the need for specialized DXA scans.
  • Temporalis Muscle as a Proxy: The temporalis muscle, located in the temple area, is hypothesized to reflect overall skeletal muscle health, making its thickness a potential indicator of sarcopenia.
  • Practicality in AD Research: If TMT proves to be a reliable biomarker, it could significantly streamline sarcopenia assessment in AD studies, allowing for more integrated and efficient data collection.

Key Results

The study included 95 participants with a mean age of 69.1 ± 5.2 years, of whom 53% were female. The median Montreal Cognitive Assessment score was 27. Eleven percent of participants met the criteria for sarcopenia.

  • Moderate Correlation: TMT showed a moderate correlation with ASM (r = 0.41, 95% confidence interval 0.23-0.56).
  • No Age Correlation: TMT did not correlate with age in this cohort.
  • Sarcopenia Distinction: TMT differed significantly between participants with and without sarcopenia. Those with sarcopenia had a mean TMT of 7.4 ± 1.2 mm, compared to 6.2 ± 0.8 mm in those without sarcopenia (p = 0.004).

Limitations and Future Work

The authors acknowledge that further studies are needed. While TMT demonstrated a moderate correlation with ASM in healthy older adults, this is a first step. Future research should focus on:

  • Replication in AD Patients: Investigating the relationship between TMT and sarcopenia in individuals diagnosed with AD.
  • Clinical and Functional Outcomes: Exploring how TMT relates to long-term clinical and functional outcomes in AD patients. This would help establish the clinical relevance of TMT as a biomarker.

Summary updated

Abstract

Among a cohort of cognitively-unimpaired older adults, TMT demonstrated moderate correlation with ASM. While futher studies are needed, these findings suggest that MRI-based assessement of TMT could be a practical tool to diagnose sarcopenia in AD studies. Future studies in AD patients should explore the relationship between TMT and long-term clinical and functional outcomes.
BibTeX
@inproceedings{huynh2025temporalis,
  author = {Andrew Huynh and Scott Wrigley and John J. Andrews and Belinda M. Brown and Sanka Amadoru and Qiongshi Lu and Ting Ye and Jeremiah J. Peiffer and Paul K. Crane and C. Rowe and Louise M. Burrell and Paul A Yates},
  title = {{Temporalis muscle thickness as a biomarker for sarcopenia: correlation with appendicular skeletal muscle mass in healthy older adults}},
  booktitle = {Alzheimer},
  year = {2025},
  doi = {10.1002/alz70856\_101748},
}
Figure